Maraviroc, an inhibitor of chemokine receptor type 5, alleviates neuroinflammatory response after cerebral Ischemia/reperfusion injury via regulating MAPK/NF-κB signaling

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations

Medicine, Medicinal Chemistry, Pharmacology +17

Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice

Sabrina Cipriani, Daniela Francisci, Andrea Mencarelli et al. · Circulation · 2013 · 148 citations

Medicine, Cardiology, Pharmacology +17

Chemokine Signaling Pathway Involved in CCL2 Expression in Patients with Rheumatoid Arthritis

Lin Zhang, Min Yu, Jiayin Deng et al. · Yonsei Medical Journal · 2015 · 76 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

CC Chemokine Receptor 5 (CCR5) Desensitization

Jean-Michel Escola, Gabriel Kuenzi, Hubert Gaertner et al. · Journal of Biological Chemistry · 2010 · 75 citations · Full text

Medicine, Cell Biology, Pharmacology +17

CCR5 and FPR1 Mediate Neutrophil Recruitment in Endotoxin-Induced Lung Injury

Jochen Grommes, Maik Drechsler, Oliver Soehnlein · Journal of Innate Immunity · 2013 · 65 citations · Full text

Life Sciences, Cell Biology, Immunology +17